Skip to content

Induction Agent Choice With Early Mortality and Prognostic Outcomes in Critically Ill Patients

Association of Induction Agent Choice With Early Mortality and Prognostic Outcomes in Critically Ill Patients: A Large-Scale Retrospective Cohort Analysis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07222007
Enrollment
4
Registered
2025-10-29
Start date
2026-04-18
Completion date
2026-07-01
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Airway Management, Critically Ill, Intubation Complication, Ketamine, Oxygenation, Propofol

Keywords

intubation, critically ill patients, airway management

Brief summary

The aim of this retrospective cohort study is to compare the safety and efficacy of induction agents for tracheal intubation in critically ill adult patients.

Detailed description

Endotracheal intubation is an accepted procedure to optimize oxygenation and ventilation and reduce the risk of aspiration for critically ill patients, essential for their management and survival across various settings, including prehospital care, emergency departments (EDs), and intensive care units (ICUs). Despite advancements, peri-intubation complications and hemodynamic instability, which are associated with increased mortality rates, remain a concern. These risks are exacerbated by pathophysiological factors in critically ill patients compared to those undergoing intubation in surgical settings . A recent international, multicentre, prospective cohort (INTUBE) study of 2964 critically ill patients undergoing tracheal intubation in the ICU, emergency department, or inpatient wards in 29 countries across five continents reported that the most frequently used agents for induction were Propofol (41.5%), Midazolam (36.4%), Etomidate (17.8%), and Ketamine (14.2%). The choice of induction agent for intubation may have the potential to minimise or exacerbate complication and mortality. Although considerable research has been carried out, critical central question concern which induction agent is most effective in minimizing cardiovascular instability during intubation. As Kotani and Risotto declared in their recent systematic review, the available findings are insufficient to support conclusive statements. Further studies are needed to identify the optimal agent and dosage, taking into account patient variability and concurrent therapeutic interventions. Understanding the impact of induction agent selection in critically ill patients has the potential to guide clinical practice in emergency and intensive care settings. Identifying agents with improved survival and prognosis would optimize patient management and inform decision-making for airway management in this vulnerable population. Moreover, delineating which agents exert minimal adverse effects on mortality and prognosis may provide valuable insight for anesthesiologists, intensivists, emergency medicine physicians, and trauma physicians.

Interventions

PROCEDUREinduction type for intubation in ICU

Clinical data documented throughout the course of hospitalization will be retrieved and analyzed.

Sponsors

Zeliha Alicikus
Lead SponsorOTHER_GOV
University of Florida
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years * Admission to the surgical ICU for critical care * Administration of one of the studied induction agents * Availability of complete clinical data

Exclusion criteria

* Age \< 18 years * Absence of documented induction agent administration * Incomplete or missing medical records

Design outcomes

Primary

MeasureTime frameDescription
Primary Outcome will be all-cause mortality at day 7 following tracheal intubationday 7mortality at day 7

Secondary

MeasureTime frameDescription
Peri-intubation cardiovascular collapseperioperativelyoccurrence after induction
Clinical course outcomesdayshospital mortality

Countries

United States

Contacts

CONTACTTOLGA SARAÇOĞLU, Prof,MD
kemaltolgasaracoglu@gmail.com+1 (904) 524-5932
CONTACTTolga Saraçoğlu, Asc Prof,MD
kemaltolgasaracoglu@gmail.com+1 (904) 524-5932
PRINCIPAL_INVESTIGATORTOLGA SARAÇOĞLU, Prof,MD

Florida University Jacksonville

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 15, 2026